Regenxbio (RGNX) Income from Continuing Operations (2014 - 2025)

Regenxbio's Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 67167000.0 for Q4 2025.

• In Q4 2025, Income from Continuing Operations fell 31.01% year-over-year to 67167000.0; the TTM figure through Dec 2025 stood at 193961000.0 (up 14.66% YoY), while the FY2025 annual figure was 193961000.0, up 14.59% from the prior year.
• Income from Continuing Operations was 67167000.0 for Q4 2025 at Regenxbio, down from 61960000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 294023000.0 in Q4 2021 to a low of 76723000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 27847550.0 across 5 years, with a median of 61914000.0 in 2023.
• Biggest YoY gain for Income from Continuing Operations was 392.34% in 2021; the steepest drop was 764.37% in 2021.
• A 5-year view of Income from Continuing Operations shows it stood at 294023000.0 in 2021, then fell by 25.04% to 220406000.0 in 2022, then tumbled by 128.57% to 62969000.0 in 2023, then grew by 18.58% to 51269000.0 in 2024, then plunged by 31.01% to 67167000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 67167000.0 (Q4 2025), 61960000.0 (Q3 2025), and 70892000.0 (Q2 2025), per Business Quant data.